ArticleNutrients2025
Assessing Sarcopenia, Presarcopenia, and Malnutrition in Axial Spondyloarthritis: Insights from a Spanish Cohort.
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of Low Free T3 with Disease Presence and Activity in Ankylosing Spondylitis.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesSarcopenia, defined by a loss of muscle mass, strength, and function, is a potential comorbidity in axial spondyloarthritis (axSpA). Its prevalence, along with malnutrition, remains unclear.
methodsThis cross-sectional study assessed sarcopenia (using the European Working Group on Sarcopenia in Older People (EWGSOP-2) criteria), presarcopenia, and malnutrition (using the Global Leadership Initiative on Malnutrition (GLIM) criteria) in a Spanish axSpA cohort. We included 94 patients aged ≥ 50 years. Sarcopenia was evaluated using the SARC-F questionnaire and by measuring muscle strength, mass, and performance. Presarcopenia was defined as low muscle mass alone. Malnutrition was assessed using body mass index (BMI) and fat-free mass index (FFMI).
resultsThe prevalence of sarcopenia, presarcopenia, and malnutrition was 3.2%, 23.4%, and 10.6%, respectively. Sarcopenia correlated with worse functionality and quality of life (Bath Ankylosing Spondylitis Functional Index (BASFI) 7.6 ± 1.2 vs. 3.6 ± 2.5,
conclusionsDespite low sarcopenia prevalence, presarcopenia and malnutrition are frequent, highlighting the need for early detection in axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.